Since Trolle (1968a, b) suggested the use of phenobarbitone for treatment of neonatal hyperbilirubinaemia, a number of trials (Maurer et al., 1968; Trolle, 1968b;  Ramboer, Thompson, and Williams, 1969;  Valaes, Petmezaki, and Doxiadis, 1970; Vest et al., 1970; Stern et al., 1970; McMullin, Hayes, and Arora, 1970; Yeung et al., 1971) have shown that its administration to the mother before birth or to the infant soon after birth produced a significant reduction in plasma bilirubin levels from the 2nd to the 4th days of life. Phenobarbitone therapy started after the appearance of jaundice seemed to be far less effective, though some studies (Yeung and Field, 1969; Stern et al., 1970; Sinniah, Tay, and Dugdale, 1971) have shown reduced need for exchange transfusions and lower plasma bilirubin levels, while others (Levin, McMullin, and Mobarak, 1970; Cunningham, Mace, and Peters, 1969) have found no significant difference.
The possible adverse effects of phenobarbitone on the neonate have been reviewed by Wilson (1969) . There are theoretical risks that the liver cells affected by phenobarbitone may become more susceptible to hepatotoxic drugs or that an increase in microsomal Received 9 February 1973. enzyme activity may accelerate the metabolism of certain drugs rendering them less effective (Burns, 1964; Fouts, 1964; Conney, 1967) . Sexual and behavioural development might be affected as a consequence of possible alteration in steroid metabolism (Conney and Klutch, 1963; Kuntzman et al., 1964; Kuntzman, Lawrence, and Conney, 1965) . Large doses of barbiturates in mothers have also been reported to produce coagulation defects in newborn infants (Schulz and van Creveld, 1958; Mountain, Hirsh, and Gallus, 1970) . As the excretion of barbiturates in the newborn is extremely variable (Melchior, Svensmark, and Trolle, 1967) , significant levels may be present in some infants for days or weeks while others excrete the drug within 2 days. Intravenous barbiturates used for sedation in labour can affect the infant's ability to suck and lead to reduced milk intake (Kron, Stein, and Goddard, 1966) . To date, however, no immediate or serious side effects have been reported from the clinical trials in which phenobarbitone was given to mothers and infants, though no long-term follow-up report has yet been published.
It was therefore decided to compare phenobarbitone treatment with phototherapy for the treatment of jaundice. Phototherapy has been Roles of phototherapy and phenobarbitone in treatment of nonhaemolytic neonatal jaundice 705
shown to be effective (Broughton et al., 1965; Lucey, Ferreiro, and Hewitt, 1968; Behrman and Hsia, 1969) even when treatment was not started until significant jaundice (plasma bilirubin > 15 mg/100 ml) had developed (Wong, Shuttleworth, and Wood, 1972) . Furthermore, since the known mechanisms for reduction of jaundice by phenobarbitone and phototherapy are unrelated, it was decided to study the effect of these 2 treatments combined.
Materials and methods
Only those infants whose plasma bilirubin levels rose to 15 mg/100 ml and above were included. (Wong et al., 1972) had shown that about a third of the controls required therapy because the bilirubin level was rising to 20 mg/100 ml. 8 babies from a previous trial were therefore used as controls.
Total bilirubin was measured by the spectrophotometric method of Scott (1959) . Plasma albumin was measured by a modification of the bromocresol green dye binding method of Bartholomew and Delaney (1966) . Residual albumin binding capacity (RABC) was measured using the HBABA dye method of Porter and Waters (1966) and was expressed as g albumin reserve/100 ml plasma (Wood, Comley, and Sherwell, 1970) . Results Infants above 2-5 kg birthweight (Trial A).
14 infants were entered into the trial in each group and the mean values of birthweight, gestation, and age at onset of phototherapy in each group, with 1 SD, are shown in Table I. All infants who received only phototherapy responded satisfactorily and no further treatment was required. Of the group given phenobarbitone alone, 3 had bilirubin levels reaching 20 mg/100 ml and were given other treatment, leaving 11 for comparison. In the combined group 1 infant was given an exchange transfusion as the bilirubin rose to 20 mg/100 ml, while 2 infants developed severe infections 36 to 48 hours after onset of treatment (see Discussion) so that again 11 were left. Of the 8 infants in the control group, 3 had to be given treatment as their bilirubin levels reached 20 mg/100 ml, leaving only 5 for comparison in the results.
The mean drop or rise was obtained by calculating the difference from the pretreatment level in each infant and then averaging the sum of the differences. The significance of the mean between groups was calculated using Student's 't' test. All results on differences were calculated in this way.
The changes in bilirubin levels are shown in Fig.  1 The changes in the various levels are shown in Fig. 2 and Table IV. Again there were no significant differences in the PCV between groups.
Discussion
In both trials the only differences between the groups lay in the bilirubin levels.
Despite higher starting levels, the group on phototherapy only and the combined groups had significantly lower bilirubin levels than both the control and the phenobarbitone groups within 24 hours of onset of treatment, and this was maintained at 60 hours. In the infants over 2-5 kg (Trial A) the phenobarbitone group fell no faster than the controls up to 60 hours, but at 84 hours the bilirubin level had fallen close to that of the other 2 treated Roles ofphototherapy and phenobarbitone in treatment of nonhaemolytic neonatal jaundice 707 to be given other treatment, it appears that in clinical practice the effect of phenobarbitone is too slow to control a rising plasma bilirubin level once it has reached 15 mg/100 ml or more. Combining phototherapy with phenobarbitone did not produce any difference in bilirubin levels compared with phototherapy alone throughout the 60 hours of phototherapy. The rate of fall from 60 to 84 hours appeared faster in the combined groups compared with phototherapy only (Fig. 1 and 2 ), but the end points did not differ significantly.
Our results on combined therapy of infants >2-5 kg birthweight are in agreement with the findings of Valdes et al. (1971) and Blackburn, Orzalesi, and Pigram (1972) who showed no difference in plasma bilirubin levels when compared with those treated with phototherapy alone. In these studies, however, treatment was started within 24 hours after birth.
There were 2 deaths in the present trial; both received phenobarbitone combined with phototherapy. shown to have a similar effect to phenobarbitone when administered to the mother in the prevention of hyperbilirubinaemia in the newborn (Waltman et al., 1969) . In the study of Levin et al. (1970) phenobarbitone was given in linctus simplex (which also contains ethanol) and the controls also received linctus simplex, so that both groups received some form of enzyme inducer. In other studies phenobarbitone 'syrup' was given with no reference as to whether the controls received any syrup or not. It is probable that some of these infants received elixir phenobarbitone (with ethanol as vehicle) while others received phenobarbitone in another solvent or in a suspension. The differences in the findings could well be explained in this way. Certain preparations of phenobarbitone sodium BP for injection contain alcohol, but in the present study phenobarbitone sodium BP (McCarthy's Ltd.) was used with propylene glycol as the vehicle, which has been shown to have no enzyme induction properties (Zarolinski, Browne, and Possley, 1971) .
